Urihk Pharmaceuticals
  • Home
  • About Us
    • Our Team
    • The Urihk Partnership
  • Products
    • Antibiotic
    • Antifungal
    • Antioxidant
    • Immuno modulator
    • Neuro/CNS
  • Services
  • Learn More
    • News
    • Gallery
    • Careers
  • Contact Us
Select Page
Back
Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry
Oct 26, 2021

Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry

Antimicrobial Susceptibility Patterns of an Emerging Multidrug Resistant Nosocomial Pathogen: Acinetobacter baumannii.
Oct 26, 2021

Antimicrobial Susceptibility Patterns of an Emerging Multidrug Resistant Nosocomial Pathogen: Acinetobacter baumannii.

Once daily high dose tigecycline-pharmacokinetic/ pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited
Oct 26, 2021

Once daily high dose tigecycline-pharmacokinetic/ pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited

Clinical experience with tigecycline in the treatment of hospital
Oct 26, 2021

Clinical experience with tigecycline in the treatment of hospital

ABOUT URIHK

URIHK pharmaceuticals is a wholly owned subsidiary of UREKA Hong Kong Ltd. We are a vertically integrated pharmaceutical company that launches, registers and distributes innovative products in India.
 

SITEMAP

About Us

Services

Products

Careers

Privacy Policy

CONTACT US

602-603, Sai Samarth Business Park,
Deonar, Govandi (East),
Mumbai (400088), India
Phone: +91 22 497 01103 / 43286
Email: [email protected]